American Samoa vs Niue: Prevalence rate of obesity in adults
American Samoa
75.9%
in 2024
Niue
66.9%
in 2024
American Samoa rank
1st
Niue rank
6th
Prevalence rate of obesity in adults over time
- American Samoa
- Niue
How they compare
American Samoa currently reports 75.9% against 66.9% in Niue, a difference of 9.0%.
That makes American Samoa's figure about 1.1 times Niue's.
Across all 45 years both countries report, American Samoa has been ahead every year.
American Samoa ranks 1st and Niue ranks 6th of 199 countries.
American Samoa has averaged higher in every one of the 5 decades both report.
Head to head by decade
| Decade | American Samoa | Niue | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 57.4% | 44.4% | 13.0% | American Samoa |
| 1990s | 66.0% | 51.8% | 14.2% | American Samoa |
| 2000s | 70.0% | 57.3% | 12.6% | American Samoa |
| 2010s | 73.2% | 62.4% | 10.8% | American Samoa |
| 2020s | 75.3% | 66.0% | 9.4% | American Samoa |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of obesity in adults, American Samoa or Niue?
- American Samoa, at 75.9% against 66.9% in Niue as of 2024.
- What is the difference in prevalence rate of obesity in adults between American Samoa and Niue?
- 9.0%, with American Samoa ahead.
- How many years of comparable data are there for American Samoa and Niue?
- 45 years are reported by both, from 1980 to 2024.
- How do American Samoa and Niue rank globally for prevalence rate of obesity in adults?
- American Samoa ranks 1st and Niue ranks 6th of 199 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) β with minor processing by Our World in Data, published as Prevalence rate of obesity in adults. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated prevalence of obesity in adults, based on general population surveys and statistical modeling. Obesity is a risk factor for chronic complications, including cardiovascular disease, and premature death.